3D image of immune cells and DNA helixes
3D image of immune cells and DNA helixes
Logo

Enabling allogeneic cell therapy manufacturing

Allogeneic cell therapies are transforming medicine. These off-the-shelf solutions can treat multiple patients and include emerging approaches like allogeneic CAR T cell therapy.1,2 They provide faster treatment at the point of care, consistent quality, and scalable production, along with reduced risks, as seen in allogeneic NK cell therapy with reduced cytokine release syndrome.3 Compared to autologous therapies, manufacturing costs are lower. Yet expanding cell production and maintaining optimal growth conditions remain challenging. Choosing the right partner is essential to establishing a robust, commercial-grade workflow.

Scalable solutions for allogeneic cell therapy manufacturing

At Miltenyi Biotec, we support the entire spectrum of cell therapy modalities, empowering both autologous and allogeneic approaches whether in clinical research or commercial settings. Our CliniMACS® Instruments, consumables, and reagents provide essential tools needed to achieve optimal growth conditions and create streamlined scalable allogeneic workflows. With flexibility built in, you can seamlessly integrate external expansion systems, such as bioreactors, to meet diverse manufacturing needs. This adaptability makes it easier to advance modalities like allogeneic stem cell therapy or allogeneic CAR T cell therapy.

Our solutions are the perfect pieces to complete your cell manufacturing puzzle. By combining our systems and taking advantage of our Customized Application (CAP) Services, you can tailor workflows from early research to commercial-scale production.

Expanding possibilities: flexible solutions for scalable manufacturing

Click to transform the base workflows into tailored solutions!

Our platforms for streamlined allogeneic workflows

A person is operating the CliniMACS Plus instrument for automated cell separation for clinical-scale cell enrichment or depletion
CliniMACS Plus Instrument

The CliniMACS Plus System in allogeneic therapies and large-scale expansion

We know that every workflow is unique, and the need to enrich or deplete certain cell types requires maximum flexibility, not only in terms of timing, but also in maintaining a closed and aseptic system.

The CliniMACS Plus System automates cell separation, enabling clinical-scale enrichment of target cells or depletion of unwanted cells from various materials. The CliniMACS Plus Instrument has been successfully used to isolate NK cells and, when combined with external vessels, supports large-scale expansion for allogeneic NK cell therapy.4,5

A person in a clean room operating the CliniMACS Prodigy cell manufacturing platform
CliniMACS Prodigy Instruments

The CliniMACS Prodigy®: a scalable platform for allogeneic cell and gene therapy

Do you need to genetically engineer, concentrate, or formulate your cell product? With the CliniMACS Prodigy, automation and standardization come together with flexibility and versatile software, allowing you to design your ideal workflow. Extensively used in the autologous setting, several studies have shown that integrating the CliniMACS Prodigy with external vessels for large-scale expansion results in even higher cell yields.6,7

Cell types and product solutions for allogeneic manufacturing

Unlock the potential of diverse cell types for allogeneic applications, including T cells, NK cells, and mesenchymal stem cells. Whether you are expanding cells for allogeneic stem cell therapy, developing allogeneic CAR T cell therapy protocols, or working with iPSC-derived immune cells, our comprehensive portfolio supports each step, from basic expansion to complex genetic modification and large-scale bioreactor workflows.

Explore the table below to see how our products support the manufacturing of various cell types.

Cell typeCell selectionActivation/
stimulation
Transduction/
electroporation
ExpansionFinal cell productIn-process control/release testing via flow cytometry
αβ T cells

Suited for CAR T and TCR engineering, offering off-the-shelf scalability and reduced GVHD.
- CliniMACS Reagents CliniMACS CD4, CD8 and CD62L Product Line- MACS® GMP T Cell TransAct™
- MACS GMP Cytokines: (MACS GMP Recombinant Human IL-2, IL-7, IL-15)
- MACS GMP Vectofusin®-1
- CliniMACS Electroporation Buffer
- TexMACS™ GMP Medium
-MACS GMP Cytokines: (MACS GMP Recombinant Human IL-2, IL-7, IL-15)
- CliniMACS Formulation Solution
- CryoMACS® Freezing Bags
- REAfinity Recombinant Antibodies (TCRα/β, CD4, CD8)
- CAR Detection Reagents
- MHC multimers
NK cells

Naturally tumor-targeting cells with non-MHC-restricted activity, ideal for scalable, off-the-shelf use.

- CliniMACS Reagents CliniMACS CD3, CD56 Product Line
- MACS GMP Cytokines: (MACS GMP Recombinant Human IL-1β, IL-2, IL-12, IL-15, IL-18, IL-21)
- MACS GMP Vectofusin®-1- NK MACS GMP Medium
- MACS GMP Cytokines: (MACS GMP Recombinant Human IL-1β, IL-2, IL-12, IL-15, IL-18, IL-21)
- CliniMACS Formulation Solution
- CryoMACS Freezing Bags
- REAfinity Recombinant Antibodies (CD56, CD16, KIR2DL1)
- NK Cell Express Mode Package
- CAR Detection Reagents
γδ T cells

Non-MHC-restricted activity supports broader donor compatibility and lower GVHD risk.
- CliniMACS Reagents CliniMACS TCRαβ, CD19 Product Line
- MACS GMP Cytokines: (MACS GMP Recombinant Human IL-1β, IL-2, IL-4, IL-7, IL-15, IL-18, IL-21)
- MACS GMP Vectofusin®-1- TexMACS GMP Medium
- MACS GMP Cytokines: (MACS GMP Recombinant Human IL-1β, IL-2, IL-4, IL-7, IL-15, IL-18, IL-21)
- CliniMACS Formulation Solution
- CryoMACS Freezing Bags
- REAfinity Recombinant Antibodies (CD3, TCRγ/δ, TCRα/β)
- γδ T cell Immunophenotyping panel (human)
- MACSPlex Cytokine Kits
iPSCs

Renewable donor cells for uniform, large-scale production, ready for precise engineering.
   Undifferentiated iPSCs:
- iPS-Brew GMP Medium
- MACS GMP Cytokines (Activin A, FGF-2, TGF-β1, SHH (C24II))
- CryoMACS Freezing Bags- PSC Analysis Cocktail Kit, anti-human
- Trilineage differentiation potential panel (hPSCs)
HSCs

An established allogeneic backbone that supports expansion and genetic modification.
- CliniMACS CD34 Product Line- HSC-Brew GMP Medium
- MACS GMP Cytokines (MACS GMP Recombinant Human FLT3L, IL-3, IL-6, SCF, TPO)
- MACS GMP Vectofusin®-1
- HSC-Brew GMP Medium
- MACS GMP Cytokines (MACS GMP Recombinant Human FLT3L, IL-3, IL-6, SCF, TPO)
- CryoMACS Freezing Bags- CD34 Stem Cell Analysis Cocktail, anti-human
- StemMACS™ HSC-CFU Assay Kit, human
- REAfinity Recombinant Antibodies (CD34, CD90, CD133)
MSCs

Donor-sourced cells offering immunomodulation and scalable, patient-ready solutions.
   - MSC-Brew GMP Medium
- MACS GMP Cytokines (FGF-2, EGF, TGF-β1)
- CryoMACS Freezing Bags- MSC Phenotyping Cocktail Kit, anti-human, REAfinity
- MSC Suppression Inspector, human
- REAfinity Recombinant Antibodies (CD73, CD90, CD105)

Application note

Robust expansion of human g-NK cells in NK MACS GMP Medium

Download the application note to see how NK MACS GMP Medium drives robust g-NK cell expansion and preserves functionality, achieving higher yields than an alternative GMP-compliant medium.

Autologous vs. allogeneic cell therapy

Although both approaches rely on similar technologies for cell growth, their scalability and sourcing differ. Autologous therapies use a patient’s own cells for personalized treatment, while allogeneic therapies leverage donor cells to deliver off-the-shelf solutions that efficiently scale to treat more patients. At Miltenyi Biotec, we support both strategies with integrated technologies, consumables, and services, empowering you to establish streamlined, flexible manufacturing workflows.

Completing your workflow with advanced analytics

Researcher in clean room attire is starting an analysis on the flow cytometer MACSQuant Analyzer 16

Safe and consistent cell manufacturing depends on robust in-process controls and release testing (IPC/RT).

Samples collected during the manufacturing process are reliably analyzed on our standardized flow cytometry platform. Our comprehensive workflow includes harmonized MACSQuant® Flow Cytometers, automated data acquisition and analysis in audit-ready software, and a broad portfolio of REAfinity® Recombinant Antibodies with superior specificity and reproducibility. Miltenyi Biotec offers pretested, ready-to-use multicolor panels and cytokine multiplexing options for streamlined, high-quality analysis.

Proven solutions to streamline analytics for IPC/RT

Our cell and gene therapy services

Customized Application Services

Tailored workflows made easy

Our Customized Application (CAP) Services team works closely with you to translate manual protocols into streamlined, integrated, and GMP-compliant workflows on the CliniMACS Prodigy. We have extensive experience supporting allogeneic applications, with more than half of our CAP projects dedicated to allogeneic cell therapies. This ensures that every step of your process meets the highest standards for efficiency and consistency.

Design your workflow

Miltenyi Bioindustry as a CDMO service provider for the development and manufacturing of lentiviral vectors and CGT products
Miltenyi Bioindustry

CDMO services for seamless advancement

Miltenyi Bioindustry provides CDMO services, offering end-to-end support to advance your cell and gene therapy programs from early development to GMP manufacturing. Scale with confidence, knowing your processes are robust, reliable, and fully supported by our expertise.

Partner with us

Get personalized support for your allogeneic cell therapies manufacturing

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. For complete regulatory notes, please click here.